Hierarchy of oncogenic gene mutations in gastric carcinogenesis

胃癌发生中致癌基因突变的层次

• 批准号: 10831328
• 负责人: Eunyoung Choi
• 金额: $ 18.4万
• 依托单位: VANDERBILT UNIVERSITY MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-01 至 2027-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10831328
• 关键词: Address; Adenocarcinoma; Automobile Driving; Cancer Etiology; Cancerous; Cell Lineage; Cells; Cessation of life; Chief Cell; Chronic; Clonal Evolution; Derivation procedure; Dysplasia; Epigenetic Process; Evolution; Gene Activation; Gene Mutation; Genetic Transcription; Goals; Heterogeneity; Human; In Vitro; Inflammation; Injury; Intestinal Intraepithelial Neoplasia; Intestinal Metaplasia; Metaplasia; Modeling; Molecular; Mucous Membrane; Mutation; Neoplastic Processes; Oncogenic; Organoids; Patients; Population; Process; Property; Recovery; Sampling; Stomach; Therapeutic Intervention; Transgenic Mice; carcinogenicity; cell type; gastric cancer prevention; gastric carcinogenesis; high risk; in vivo; interest; malignant stomach neoplasm; mouse model; neoplastic; novel; precursor cell; premalignant; response; response to injury; spasmolytic polypeptide; stem cells; transdifferentiation; tumor progression

ABSTRACT This application is being submitted in response to the Notice of Special Interest (NOSI) identified as NOT-CA-23-045. Gastric cancer is the 4th leading cause of cancer-related death worldwide and it most commonly develops within a carcinogenic cascade from pre-cancerous metaplasia to dysplasia and adenocarcinoma. Metaplasias first arise as a response to injury through the chief cell transdifferentiation into spasmolytic polypeptide- expressing metaplasia (SPEM) cells. While this initial process is possibly reversible, oncogenic gene activation or chronic inflammation can activate SPEM cell plasticity, which promotes SPEM cell progression to intestinal metaplasia (IM) and dysplasia. This neoplastic process may also lead to transcriptional and epigenetic changes, and incite cell lineage conversion, where multiple intermediate cell types are produced that can evolve into cancerous cells, including dysplastic stem cells which may arise during the neoplastic transition. Furthermore, the oncogenic gene mutation burden may be associated with the cell lineage conversion and diversification of the dysplastic stem cells to cancerous cells. However, it is not clear whether the SPEM cell plasticity is responsible for the cell heterogeneity and evolution of pre-cancerous metaplasia to incomplete IM, which carries a higher risk of patient progression to dysplasia and what mechanisms are involved in the carcinogenic process. We therefore hypothesize that SPEM cells are key gastric cancer precursor cells, which display functional properties and cell lineage conversion capacity to drive metaplasia progression to dysplasia. Our overarching goal is to define mechanisms that control the cell lineage conversion of reparative SPEM cells towards incomplete IM and more cancerous cell lineages, which display a higher mutational burden. To address these questions directly, we have established novel in vivo transgenic mouse models and in vitro metaplastic or dysplastic organoid models derived from transgenic mouse stomachs following induction of active Kras or from human patient samples with metaplasia or dysplasia. Using these novel models, we will assess critical SPEM cell lineage derivation and define cell populations that account for the key transcriptional and epigenetic changes arising during metaplasia progression. We will pursue three specific aims: First we will assess functional properties of SPEM cells during mucosal recovery or neoplastic progression following mucosal injury. Second, we will examine regulatory mechanisms of cell lineage diversification and conversion during metaplasia progression. Third, we will investigate molecular mechanisms driving cell linage diversification and clonal evolution of dysplastic stem cells to adenocarcinoma. Our studies will define critical transition points which lead to neoplastic transitions for SPEM cells as the origin of gastric carcinogenesis. An understanding of regulatory mechanisms in cell plasticity and the ability to reverse such transitions could lead to therapeutic interventions to prevent gastric cancer.

抽象的 本申请是为了响应特殊利益通知（NOSI）而提交的，该通知被确定为 不是-CA-23-045。胃癌是全球癌症相关死亡的第四大原因，也是最常见的癌症 通常在从癌前化生到不典型增生的致癌级联中发展 腺癌。化生首先作为对损伤的反应而出现，通过主细胞转分化为 解痉多肽表达化生（SPEM）细胞。虽然这个初始过程可能是可逆的， 致癌基因激活或慢性炎症可激活SPEM细胞可塑性，从而促进SPEM 细胞进展为肠化 (IM) 和发育不良。这种肿瘤过程也可能导致 转录和表观遗传变化，并刺激细胞谱系转换，其中多个中间细胞 产生的类型可以演变成癌细胞，包括可能出现的发育不良干细胞 在肿瘤转变期间。此外，致癌基因突变负担可能与 发育不良干细胞向癌细胞的细胞谱系转化和多样化。然而，它并不是 明确 SPEM 细胞的可塑性是否与细胞异质性和癌前病变的进化有关 化生为不完全 IM，这会增加患者进展为不典型增生的风险，以及什么 机制参与致癌过程。因此，我们假设 SPEM 细胞是关键 胃癌前体细胞，显示出驱动的功能特性和细胞谱系转换能力 化生进展为不典型增生。我们的首要目标是定义控制细胞的机制 修复性 SPEM 细胞向不完全 IM 和更多癌细胞谱系的谱系转变， 显示出更高的突变负担。为了直接解决这些问题，我们建立了新颖的体内 转基因小鼠模型和源自转基因的体外化生或发育不良类器官模型 诱导活性 Kras 后的小鼠胃或来自具有化生或的人类患者样本 发育不良。使用这些新颖的模型，我们将评估关键的 SPEM 细胞谱系衍生并定义细胞 解释化生过程中出现的关键转录和表观遗传变化的群体 进展。我们将追求三个具体目标：首先，我们将评估 SPEM 细胞的功能特性 在粘膜损伤后的粘膜恢复或肿瘤进展期间。其次，我们将检查 化生进展过程中细胞谱系多样化和转化的调节机制。第三，我们 将研究驱动细胞谱系多样化和发育不良干细胞克隆进化的分子机制 细胞转变为腺癌。我们的研究将确定导致肿瘤转变的关键转变点 SPEM细胞是胃癌发生的起源。了解细胞调控机制 可塑性和逆转这种转变的能力可能会导致预防胃病的治疗干预措施 癌症。